Member Info for robrob

you buying?

what does that tell us?

RNS IMO is overall positive, agree with you Kierewiet in that to get this moving and rewards shareholders there are future options to make placings. These don't have to be discounted and could be positioned as premium placings prior to JUV IPO pre October, Emmac development prior to their IPO etc.

Cash is king at these times, so for FFWD to succeed I can see why they want to do this.

Been more movement since Ed has taken over and we are seeing more activity. Would have been nice to see a £££ type of RNS but I think we'll get these in due course.

oh doggo, but you're the most opinionated person on this bb. IMO. I fell off my chair laughing when you wrote...

"Step up. You post plenty of opinion about me for some reason'

You've relentlessly put down and scared off the vast majority of posters on this board for years and years, day in day out, with your personal opinion led replies aimed quite directly at every single poster to this board.

...for further buys I'd like some clarity on

Leap, is this a IPO, sale, dividend etc
Emmac, is this a IPO this year
Emmac covid update

Good question Matt, be good to get everyone's views from those in or on the fence

Surprised that no one is asking what the 'slight dilution' is.

At 1.18 % the dilution issued could be ???

Chinese scientists have been developing a drug they believes has the power to stop the Covid-19 pandemic in its tracks – even without a vaccine.

https://icg.pku.edu.cn/en/index.htm

Researchers at Peking University are testing a drug which could both shorten the recovery time for infected patients, and has the potential to offer short-term immunity from the coronavirus.

Sunney Xie, director of the university's Beijing Advanced Innovation Center for Genomics, told AFP that the drug has been successful at the animal testing stage.

“When we injected neutralising antibodies into infected mice, after five days the viral load was reduced by a factor of 2,500,” Xie said, adding that his team’s expertise is single-cell genomics rather than immunology or virology.

“When we realised that the single-cell genomic approach can effectively find the neutralising antibody we were thrilled."

Neutralising antibodies are produced by the human immune system to prevent the virus infecting cells. Xie's team isolated from the blood of 60 recovered patients.

Published in the scientific journal Cell, the study suggests that using the antibodies provides a potential "cure" for Covid-19.

Share the research Dr.

yeh it is
twitter dot com. then /SkyNewsBreak/status/1255794414410137601

Chief executive of pharmaceutical giant AstraZeneca has told Sky News it should know if a potential COVID-19 vaccine it is working on with a team of scientists from the University of Oxford works "by June to July"

via twitter
/SkyNewsBreak/status/1255794414410137601

“...does look very promising”

:)

Yes the RNS is an easy read.

The social media thread is likely to be (for those who are interested)

@AlbertEdwardJa1
#HEMO extract just issued results
In 2019, we began our efforts to leverage our mouse technology for these purposes, and in view of the recent crisis arising from the COVID-19 pandemic we have now initiated work in a NUMBER of areas related to COVID-19
as we recently announced.

so it's reported as :

- 10.687M loss on the years activity
- 16.5M shareholder funds in place

All things considered they have done very well for the acquisitions , fund raising and expansion IMO. Good balance sheet for what I believe they are wanting to achieve.

Cost of sales looks very healthy considering the scalability and expansion I suspect is coming, based on the market size and what they can win of future market share it does look very promising.

GLA

sorry mobile phone characters there (?)... !

I’ve had a small holding in HEMO for some time what attracted me initially was the June 2019 announcement for wide ranging use of the novel applications they started work on??? June 2019 ?

https://www.morningstar.co.uk/uk/news/AN_1561376555206330000/hemogenyx-creates-humanised-mouse-without-graft-versus-host-disease.aspx??

Hemogenyx's novel mouse has a possible use in testing multi-specific antibodies, including its own bi-specific CDX antibody.

This has potential in the elimination of acute myeloid leukemia, as well as for conditioning patients for a bone marrow transplant.??

Bear in mind that bone marrow transplantation (BMT) accounted for $810 million with procedure costs averaging between $100,000 and $300,000 per patient, making it one of the single most costly health care procedures in USA alone. No one knows what the 'cure' for COVID-19 is worth, but it will be staggering.

??April 2020
?Humanised mice for the COVID-19 testing of human vaccines is a game changer on top of a game changer. As we know being able to test, test, test in volume and without risking human life is priceless??.

As alluded there are big names involved both from the scientific field and commercially.?? The application for HEMO is staggering, it's no wonder we have Marc Feldman as Chair.

May 2020
I'm expecting new announcements from the work that has been completed over the last eleven months and detailing of the application to COVID-19.

Hold on to your hats. ? IMO this is the beginning and will scale above and beyond where we are now in terms of MCAP.

GLA. DYOR.

ODonnell,

there will have to be sellers for there to be buyers...

what are you trying to say.

Thats a good reminder Tilburn. Good to share.

Looking forward to the newsflow coming...

Me too

Matter of time now

no harm in dreaming, but think we'll see the 1p.

16% up.

Oldabutnowisa,

Boy, you sound like O’Donnell with all that use of “we” in your post today. Are you O’Donnell?

“wadnob - I take it you are being funny! If they cannot get funding for Factom after hunting around for a long time, as the largest holder of their stock, we are going to lose heavily. And since we are an IT, we cannot take it over and run it even if we wanted to. It just goes to show that bad news happens fast, great news filters out slowly. Even you can't put a shine on this!”